These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1476620)

  • 1. Bispecific antibodies.
    Fanger MW; Morganelli PM; Guyre PM
    Crit Rev Immunol; 1992; 12(3-4):101-24. PubMed ID: 1476620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human monocyte-mediated cytotoxicity: the use of Ig-bearing hybridomas as target cells to detect trigger molecules on the monocyte cell surface.
    Graziano RF; Fanger MW
    J Immunol; 1987 Feb; 138(3):945-50. PubMed ID: 2949010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
    de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
    Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
    Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
    Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functions of the various IgG Fc receptors in mediating killing of Toxoplasma gondii.
    Erbe DV; Pfefferkorn ER; Fanger MW
    J Immunol; 1991 May; 146(9):3145-51. PubMed ID: 1826707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanisms of antibody-dependent killing mediated by lymphoid and myeloid cells are distinct based on different divalent cation requirements.
    Graziano RF; Erbe DV; Fanger MW
    J Immunol; 1989 Dec; 143(12):3894-900. PubMed ID: 2574205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies.
    Clark MR; Waldmann H
    J Natl Cancer Inst; 1987 Dec; 79(6):1393-401. PubMed ID: 3121901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells.
    Graziano RF; Fanger MW
    J Immunol; 1987 Nov; 139(10):3536-41. PubMed ID: 2960735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ; Hillstrom JR
    J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR.
    van de Griend RJ; Bolhuis RL; Stoter G; Roozemond RC
    J Immunol; 1987 May; 138(10):3137-44. PubMed ID: 2952709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
    Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
    Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monoclonal antibodies: therapeutic possibilities and limitations].
    Tax WJ; Capel PJ; Koene RA
    Tijdschr Kindergeneeskd; 1987 Feb; 55(1):1-9. PubMed ID: 3551184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD45 molecule cross-linking inhibits natural killer cell-mediated lysis independently of lytic triggering.
    Starling GC; Hart DN
    Immunology; 1990 Oct; 71(2):190-5. PubMed ID: 2146214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
    Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
    Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
    Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
    Chen J; Zhou JH; Ball ED
    Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
    Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
    J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of functional activities of human lymphocytes by monoclonal antibodies.
    Melioli G; Prigione I; Merlì A; Cantoni C; Chen Q; Machi AM; Ferrini S
    Ann Ist Super Sanita; 1991; 27(1):79-85. PubMed ID: 1835570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of cytotoxic cells against tumors with heterocrosslinked, bispecific antibodies.
    Segal DM; Qian JH; Garrido MA; Perez P; Winkler DF; Wunderlich JR; Snider DP; Valdayo MJ; Titus JA
    Princess Takamatsu Symp; 1988; 19():323-31. PubMed ID: 3269363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.